Vaxart, Inc. (VXRT)
| Market Cap | 146.44M |
| Revenue (ttm) | 7.38M |
| Net Income (ttm) | -82.47M |
| Shares Out | 173.86M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | 45.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 807,895 |
| Open | 0.860 |
| Previous Close | 0.866 |
| Day's Range | 0.831 - 0.900 |
| 52-Week Range | 0.530 - 1.590 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+256.17%) |
| Earnings Date | May 2, 2024 |
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic... [Read more]
Financial Performance
In 2023, Vaxart's revenue was $7.38 million, an increase of 6796.26% compared to the previous year's $107,000. Losses were -$82.47 million, -23.47% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 256.17% from the latest price.
News
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccin...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approv...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended Decem...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif.
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity again...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the...
Vaxart, Inc. Announces Management Change
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D.
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosin...
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief ...
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual M...
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet done...
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for...
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxar...
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN ...
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
Company to provide a detailed overview of its norovirus clinical program
Vaxart Provides Business Update and Full Year 2022 Financial Results
Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
Conference call to begin at 4:30 p.m. ET
Vaxart Names Phillip Lee as Chief Financial Officer
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine...
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
Conference call to begin at 4:30 p.m. ET